- Home
- REFI vs CCCC Comparison
REFI vs CCCC Comparison
Compare REFI & CCCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | REFI | CCCC |
|---|---|---|
| Founded | 2021 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 255.6M | 185.1M |
| IPO Year | 2021 | 2020 |
Fundamental Metrics
Financial Performance| Metric | REFI | CCCC |
|---|---|---|
| Price | $12.44 | $2.81 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | ★ $20.00 | $12.20 |
| AVG Volume (30 Days) | 103.0K | ★ 2.9M |
| Earning Date | 06-19-2026 | 05-25-2026 |
| Dividend Yield | ★ 15.55% | N/A |
| EPS Growth | N/A | ★ 16.45 |
| EPS | ★ 1.68 | N/A |
| Revenue | ★ $48,857,628.00 | $35,947,000.00 |
| Revenue This Year | $19.62 | N/A |
| Revenue Next Year | $10.79 | N/A |
| P/E Ratio | $7.20 | ★ N/A |
| Revenue Growth | N/A | ★ 1.02 |
| 52 Week Low | $11.62 | $1.09 |
| 52 Week High | $15.67 | $3.82 |
Technical Indicators
Market Signals| Indicator | REFI | CCCC |
|---|---|---|
| Relative Strength Index (RSI) | 59.79 | 54.34 |
| Support Level | $12.23 | $2.09 |
| Resistance Level | $12.90 | $3.82 |
| Average True Range (ATR) | 0.24 | 0.33 |
| MACD | 0.03 | -0.03 |
| Stochastic Oscillator | 91.82 | 29.08 |
Price Performance
Historical ComparisonAbout REFI Chicago Atlantic Real Estate Finance Inc.
Chicago Atlantic Real Estate Finance Inc is engaged in a commercial real estate finance company. Its primary investment objective is to provide attractive risk-adjusted returns for stockholders over time, through consistent current income dividends and other distributions and secondarily through capital appreciation.
About CCCC C4 Therapeutics Inc.
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients' lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. Its degrader medicines are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT1946, and CFT8919.